Zealand Pharma A/S
Research Zealand Pharma A/S (ZEAL) on Bullrun: market cap DKK 17.74B, P/E 6.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerZEAL
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 17.74B
- P/E6.9
- Financial periodQ1 2026
- RevenueDKK 34.00M
- Net income-DKK 394.00M
- Free cash flow-DKK 683.00M
- Gross margin100.0%
Valuation Snapshot
latest market cap is DKK 17.74B; P/E is 6.9.
Peer valuation comparison
Latest P/E is 6.87x versus a Healthcare sector median of 24.6x (72.1% below).
Latest P/E is 6.87x versus a Denmark median of 17.64x (61.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 9.21B | DKK 6.46B | DKK 6.46B | 100.0% | n/a | DKK 4.58B | DKK 405.77M | DKK 14.83B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | DKK 17.74B | 6.9 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
ETFs that hold Zealand Pharma A/S
Zealand Pharma A/S is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| Deka STOXX Europe Strong Value 20 UCITS ETF | 5.07% | 0.65% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Zealand Pharma A/S's market cap?
Zealand Pharma A/S's market capitalization is DKK 17.74B.
What is Zealand Pharma A/S's P/E ratio?
Zealand Pharma A/S's price-to-earnings (P/E) ratio is 6.9.
What does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism.